Since its inception, the paradigm of health technology assessment (HTA) has been constantly evolving. This is a completely natural process given the development of medical science and the accelerated penetration of innovative health technologies.
In recent years, however, there has been a growing trend to increase transparency in pricing and to promote performance-based reimbursement of health technologies.
On July 24, 2020, Italy officially promulgated a new regulation on HTA, which, among other things, significantly increased public control over pricing and reimbursement of all new medicinal products. This article aims to summarize and critically analyze the most important of these changes and their significance for the European policy and practice in the field of HTA. Read the whole article here.